TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11198726
Drug: Cephalexin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (500 mg three times daily for 7 days)
Study: 2956200
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg nifedipine administered intracoronarily before the first transluminal occlusion and again just before the second occlusion.
Study: 2956200
Drug: Solvent administered
Normalized name: solvent yellow 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solvent administered intracoronarily before the first transluminal occlusion and again just before the second occlusion.
Study: 2956200
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg nifedipine administered intracoronarily just before the second transluminal occlusion.
Study: 26111347
Drug: Treatment adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adherence enhancement intervention
Study: 10878419
Drug: Caffeine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2.5 mg/kg once a day)
Study: 10878419
Drug: Aminophylline (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (1.25 mg/kg twice a day)
Study: 1555424
Drug: Exosurf (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosurf (5 ml/kg, intratracheal surfactant preparation)
Study: 1555424
Drug: Air (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air (5 ml/kg, control group)
Study: 3925478
Drug: Placebo (0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.0 mg)
Study: 18454655
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + doxycycline (100 mg/day for 14 days) (N = 15)
Study: 16927289
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment for longer than 1 year
Study: 15725422
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg levodopa
Study: 9061112
Drug: Bilateral maxillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral maxillary nerve block with local anaesthetics (5-10 ml of bupivacaine 0.5% and lignocaine 2%)
Study: 8448063
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg carbamazepine liquid suspension
Study: 8448063
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet formulation
Study: 8448063
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release tablet formulation
Study: 3492378
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg propyphenazone
Study: 3492378
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg propyphenazone
Study: 3178925
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetylsalicylic acid (ASA)
Study: 16898862
Drug: 3 oz
Normalized name: Oval Amber 3 oz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 oz (84 g) of almonds daily for 4 weeks
Study: 16898862
Drug: 6 oz
Normalized name: Oval Amber 16 oz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 oz (168 g) of almonds daily for 4 weeks
Study: 10802368
Drug: Concomitant boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant boost technique (CBT) radiation therapy, 46.8 Gy in 26 fractions with a concomitant boost of 18.2 Gy (0.7 Gy per fraction) to the gross disease, total dose 65 Gy in 26 fractions.
Study: 10802368
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment technique (CTT) radiation therapy, 70.8 Gy in 38 fractions.
Study: 10802368
Drug: Concomitant boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant boost technique (CBT) radiation therapy.
Study: 10802368
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment technique (CTT) radiation therapy.
Study: 8623995
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 75 mg intramuscular diclofenac, 1000 mg intravenous metamizole, 5.3 +/- 1 mg epidural morphine, and 15-20 ml mepivacaine 1% administered 85 +/- 41 min before skin incision. Epidural analgesia maintained by injections of 0.1 ml.kg‐1.h‐1 mepivacaine 1%.
Study: 3912367
Drug: Oral cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cephradine
Study: 3912367
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics after cephradine
Study: 27321485
Drug: Surgical intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical intervention model including antituberculosis drugs for at least 3 weeks, accurate wound assessment, complete excision of sinus tract and surrounding devitalized tissue, vacuum sealing drainage (VSD) for 1 to 2 weeks, followed by direct suture or grafting skin or flap.
Study: 27321485
Drug: Routine dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine dressing change every 3 days after initial antituberculosis drugs for at least 3 weeks.
Study: 17315155
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (Ara-C) (20 mg twice daily for 10 days)
Study: 15471181
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) with 2 x 2000 impulses of 0.28 mJ/mm2 at an interval of two weeks
Study: 3170089
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation of 20 mg a day
Study: 17466492
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 15 mg
Study: 15887835
Drug: Gatifloxacin 400mg
Normalized name: GATIFLOXACIN 400MG TAB
DrugBank: Gatifloxacin (DB01044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gatifloxacin 400mg single oral dose
Study: 9307648
Drug: Topical 50
Normalized name: urea topical 50% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 50 micrograms/ml latanoprost once daily from day 4 to day 18
Study: 9307648
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops once daily from day 4 to day 18
Study: 7294185
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of haloperidol
Study: 7294185
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of haloperidol
Study: 7294185
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of haloperidol
Study: 31468106
Drug: Strength and
Normalized name: Excedrin Extra Strength and Excedrin Tension Headache KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength and balance training intervention (2 months, once-weekly home-based)
Study: 25954110
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + chemotherapy (AGITG MAX trial)
Study: 25954110
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + chemotherapy (TRACC registry)
Study: 25954110
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (AGITG MAX trial)
Study: 25954110
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (TRACC registry)
Study: 25954110
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + chemotherapy (TRACC registry, patients without peritoneal metastases)
Study: 25954110
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (TRACC registry, patients without peritoneal metastases)
Study: 25954110
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + chemotherapy (MAX trial)
Study: 25954110
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + chemotherapy (TRACC)
Study: 25954110
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + chemotherapy (NSWCC)
Study: 25954110
Drug: Chemotherapy duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy duration
Study: 17014595
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg once daily (QD)
Study: 9820371
Drug: Endoscopic hemostasis
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic hemostasis (heater probe, bipolar electrocoagulation, or injection sclerosis)
Study: 9820371
Drug: Medical‐surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical‐surgical treatment
Study: 8022739
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of methylprednisolone (500 mg for three consecutive days)
Study: 8022739
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of methylprednisolone (500 mg for three consecutive days)
Study: 28490356
Drug: Miriplatin/DDP‐H combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miriplatin/DDP‐H combination therapy
Study: 28490356
Drug: Miriplatin monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miriplatin monotherapy
Study: 25809331
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose CT colonography with enhanced scanning
Study: 25809331
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose CT colonography with enhanced scanning
Study: 25809331
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose CT colonography
Study: 25809331
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose CT colonography
Study: 15098379
Drug: Raloxifene (Evista),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (Evista), one tablet daily, with or without food
Study: 7597427
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m2 infused as a single dose over 1 hour
Study: 7597427
Drug: Paclitaxel divided
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel divided into three doses infused over 1 hour on 3 consecutive days
Study: 7597427
Drug: Both infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both infusion schedules
Study: 2512129
Drug: Oral Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Ciprofloxacin (30mg/kg/day; max 1,500mg) for four weeks after initial therapy
Study: 28261001
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract 1200 mg for 6 weeks
Study: 24100691
Drug: Sparrow® drug‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparrow® drug‐eluting stent (DES)
Study: 18298503
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for 2 weeks
Study: 17201647
Drug: Phenylephrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (20 mg)
Study: 12492451
Drug: Bendroflumethiazide (TD)
Normalized name: Bendroflumethiazide
DrugBank: Bendroflumethiazide (DB00436)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bendroflumethiazide (TD) 5 mg/day
Study: 9059313
Drug: NG-Monomethyl-L-arginine
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-Monomethyl-L-arginine
Study: 2859870
Drug: Indoramin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (25 mg three times daily)
Study: 2859870
Drug: Control (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (beta blockers and nitrates continued unchanged)
Study: 22672770
Drug: Solanezumab 400
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solanezumab 400 mg weekly
Study: 22672770
Drug: Solanezumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solanezumab (various doses)
Study: 12354424
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy in hospitals with coronary revascularization capability
Study: 12354424
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy in hospitals without coronary revascularization capability
Study: 1970584
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg oral)
Study: 7069504
Drug: L-methionine (0.0605
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methionine (0.0605 mmoles/kg body weight)
Study: 7069504
Drug: N-acetyl-L-methionine (0.0605
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-L-methionine (0.0605 mmoles/kg body weight)
Study: 7069504
Drug: L-methionine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methionine and N-acetyl-L-methionine
Study: 7069504
Drug: N-acetyl-L-methionine
Normalized name: N-acetyl-methionine, DL-
DrugBank: N-Acetylmethionine (DB01646)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-L-methionine
Study: 23045575
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy and Physical Exercise (CBT/PE)
Study: 15530150
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.35 g n‐3 fatty acids)
Study: 9692655
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice/day
Study: 7841566
Drug: Nimodipine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 0.4 mg/h
Study: 7841566
Drug: Nimodipine 1
Normalized name: nimodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 1 mg/h
Study: 7841566
Drug: Vehicle 10
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle 10 mL/h
Study: 7841566
Drug: Placebo 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mL/h
Study: 7841566
Drug: Nimodipine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 0.4 mg/h and 1 mg/h
Study: 3073766
Drug: Intraarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial infusion therapy with prostaglandin E1 (PGE)
Study: 3073766
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy with energy rich phosphates (ERP)
Study: 29968385
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of oral drotaverine hydrochloride (80 mg) and paracetamol (500 mg)
Study: 29968385
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (500 mg) three times a day for 3 days
Study: 28448784
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) telephone intervention conducted by pharmacy students, including an initial call and 5 monthly follow-up calls.
Study: 25614134
Drug: Placebo HILT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo HILT (sham therapy group)
Study: 17052306
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg (for patients aged<11 years) or 400 microg administered via Turbuhaler
Study: 18405951
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus usual asthma therapy
Study: 11011847
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid, 0.4 mg vitamin B12 and 50 mg vitamin B6
Study: 9309533
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg/die orally for 7 days
Study: 8339552
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dietary changes and exercise
Study: 3730230
Drug: Alcuronium 0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.15, 0.2 or 0.3 mg kg‐1 with priming
Study: 3730230
Drug: Alcuronium 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.04 mg kg‐1 given 30 s after induction
Study: 3730230
Drug: Alcuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.3 mg kg‐1 with increased priming portion
Study: 25008027
Drug: Prasugrel 5-mg
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5-mg
Study: 25008027
Drug: Prasugrel 10-mg
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10-mg
Study: 25008027
Drug: Clopidogrel 75-mg
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75-mg
Study: 23433324
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of intramuscular 17P, repeated twice weekly until 36 weeks or preterm delivery
Study: 20101185
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting therapy (RLAT) 25 or 50 mg every 2 weeks
Study: 21999370
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting therapy (RLAT)
Study: 18439282
Drug: Ultrasound physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound physical therapy (UPT)
Study: 12672938
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation with 91 mg (136 iu) α-tocopherol and 250 mg of slow-release vitamin C twice a day for 3 years
Study: 1908372
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg q.i.d. for 4 weeks
Study: 6857507
Drug: Low‐dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐dose subcutaneous heparin
Study: 6857507
Drug: Intermittent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sequential compression and thromboembolism‐deterrent (TED) stockings
Study: 25583271
Drug: Modular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular treatment
Study: 25583271
Drug: Standard manualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard manualized treatment
Study: 24507754
Drug: Warming blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming blood transfusion and infusion (WBI)
Study: 12065142
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management of the third stage of labor with uterotonic drugs (Oxytocin preferred)
Study: 8539677
Drug: CPAP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP titration using full polysomnography
Study: 8539677
Drug: CPAP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP titration using night time respiratory recordings
Study: 2482193
Drug: Anthracyclines 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracyclines 0.2 mumol/l
Study: 2482193
Drug: Ara-C 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ara-C 0.5 mumol/l
Study: 2482193
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anthracyclines and Ara-C
Study: 2482193
Drug: Incubations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incubations with 0.2 mumol/l anthracyclines and 0.5 mumol/l Ara-C
Study: 2482193
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro drug sensitivity
Study: 27932540
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received treatment after three months
Study: 23670112
Drug: Two-session intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-session intervention aimed at increasing adherence via implementation intentions and modifying mistaken beliefs about medication/stroke.
Study: 19552805
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection with physiotherapy (8 sessions over 8 weeks)
Study: 19552805
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection with physiotherapy (8 sessions over 8 weeks)
Study: 11943519
Drug: Bupivacaine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 180 mg with midazolam 20 mg (HM group)
Study: 11943519
Drug: Bupivacaine 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 90 mg with midazolam 20 mg (LM group)
Study: 11943519
Drug: Bupivacaine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 180 mg without midazolam (HC group)
Study: 11943519
Drug: Bupivacaine 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 90 mg without midazolam (LC group)
Study: 9495418
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of alfentanil (0.36 mg/h) plus bupivacaine (10 mg/h)
Study: 9495418
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of alfentanil (0.36 mg/h) plus bupivacaine (10 mg/h)
Study: 7710445
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.i.d. and clarithromycin 500 mg q.i.d. (group 1)
Study: 7710445
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg q.i.d. and clarithromycin 500 mg q.i.d. (group 2)